When combined with immune checkpoint inhibitors, LSD1 inhibition has been found to induce interferon 1 signaling and enhance tumor response to therapy, making the agent a potential supplement to current immunotherapies approved for the treatment of MCC [88]. The gene discussed is KDM1A; the disease is neoplasm.